Table 1.
Demographic and clinical characteristics of study groups
| Schizophrenia patients (N = 31) | Unaffected siblings (N = 31) | Healthy controls (N = 31) | X 2‐value | P‐value | |
|---|---|---|---|---|---|
| Age (years), mean ± SD | 33.90 ± 8.09 | 33.29 ± 9.80 | 31.26 ± 9.14 | 1.905 | 0.386a |
| Gender, male (%) | 17 (54.8%) | 18 (58.1%) | 15 (48.3%) | 0.611 | 0.739a |
| Education (years), mean ± SD | 14.06 ± 2.06 | 15.25 ± 1.91 | 15.41 ± 2.45 | 5.922 | 0.052a |
| Right‐handed (%) | 31 (100%) | 30 (96.8%) | 31 (100%) | 2.022 | 0.313a |
| Duration of illness | 9.16 ± 5.30 | ||||
| Total antipsychotic dose, mean CPZ equivalent (mg) ± SD | 319.71 ± 156.76 |
Statistical comparison of the demographics across groups by a Kruskal‐Wallis ANOVA.
a
Chi‐square test.
Abbreviations: CPZ, chlorpromazine.